Persistent effects of doxorubicin on cardiac gene expression

Journal of Molecular and Cellular Cardiology

Volumn 31, Issue 8, 1999, Pages 1435-1446

  Boucek Jr , Robert J ^a   Miracle, Ann ^a   Anderson, Michelle ^c   Engelman, Robert ^a   Atkinson, James ^b   Dodd, Debra A ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Anthracyclines; Atrial naturetic peptide; Cardiac gene expression; Cardiomyopathy; Dihydropyridine receptor; Doxorubicin; Ryanodine receptor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALPHA ACTIN; ANGIOTENSIN RECEPTOR; ANTHRACYCLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE; DOXORUBICIN; MESSENGER RNA; MYOSIN HEAVY CHAIN; RYANODINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HEART; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROBE; SARCOLEMMA; SARCOPLASMIC RETICULUM; SOUTHERN BLOTTING;

EID: 0033178477     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1999.0972     Document Type: Article

References (48)

1. Akimoto H., Bruno N.A., Slate D.L., Billingham M.E., Torti S.V., Torti F.M. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. 53:1993;4658-4664.
2. Arai M., Suzuki T., Nagai R. Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but down regulated in severe cardiac hypertrophy induced by pressure overload. J Mol Cell Cardiol. 28:1996;1583-1590.
3. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., Nagai R. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced in doxorubicin in rabbits. J Mol Cell Cardiol. 30:1998;243-254.
4. Bauch M., Ester A., Kimura B., Victorica B.E., Keslar A., Phillips M.I. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer. 69:1992;1492-1497.
5. Bernardini N., Agen C., Favilla S., Danesi R., Del Tacca M. Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor. J Endocrinol Invest. 15:1992;79-84.
6. Billingham M.E. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver, MD (ed.), Cardiovascular Pathology, Second Edition. New York: Churchill Livingstone. 1991;1465-1486.
7. Bloch K.D., Seidman J.G., Naftilan J.D., Fallon J.T., Seidman C.E. Neonatal atria and ventricles secrete atrial naturetic factor via tissue-specific secretory pathways. Cell. 47:1986;695-702.
8. Boucek RJ Jr, Dodd D., Atkinson J., Oquist N., Olson R. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Card. 29:1997;2631-2640.
9. Burns K.D., Inagami T., Harris R.C. Cloning of rabbit kidney cortex AT1 angiotensin II receptor that is present in proximal tubule epithelium. Am J Physiol. 264:1993;F645-F654.
10. Cao L., Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 25:1995;227-234.
11. Cappelli V., Moggio R., Monti E., Paracchini F., Rggiani C. Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity. J Mol Cell Cardiol. 21:1989;93-101.
12. Chomczynski P., Sacchi N. Single-step method of isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
13. Crow M.T., Boluyt M.O., Lakatta E.G. . In: Holbrook NJ, Martin GR, Lockshin RA (eds.) Cellular Aging and Cellular Death. NY: Wiley-Liss Inc. 1996.
14. Dodd D.A., Atkinson J.B., Buck S., Fleischer S., Boucek RJ Jr. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum. J Clinical Invest. 91:1993;1697-1705.
15. Dodd D.A., Boucek RJ Jr, Atkinson J.B., Fleischer S. Chronic doxorubicin decreases calcium release channel (CRC) mRNA prior to manifestation of cardiomyopathic changes. Circ. 92:1995;I-305.
16. Dodd D.A., Summar M., Boucek RJ Jr, Atkinson J.B., Fleischer S. Chronic doxorubicin decreases CRC mRNA abundance earlier and greater than other muscle-specific and non-muscle mRNA transcripts. Biophys J. 70:1996;A53.
17. Eliopoulos A., Kerr D.J., Spandidos D.A. The effect of doxorubicin, daunorubicin and 4′-epidoxorubicin on the exogenous c-myc promotor in mouse erythroleukemia cells. Anticancer Research. 11:1991;2153-2158.
18. Feldman A.M., Weinberg E.O., Ray P.E., Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 73:1993;184-192.
19. Foglesong P.D., Reckford C., Swink S. Doxorubicin inhibits human DNA topoisomeraseI. Cancer Chemother Pharmacol. 30:1992;123-125.
20. Francis G., McDonald K. Left ventricular hypertrophy: initial response to myocardial injury. Am J Cardiol. 69:1992;3G-9G.
21. Gomez A.M., Valdivia H.H., Cheng H. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 276:1997;800-806.
22. Goorin A.M., Borow K.M., Goldman A., Williams R.G., Henderson I.G., Sallen S.E., Cohen H., Jaffe N. Congestive heart failure due to adriamycin cardiotoxicity. Cancer. 47:1981;2810-2816.
23. Ito H., Miller S.C., Billingham M.E., Akimoto H., Torti S.V., Wade R., Gahlmann R., Lyons G., Kedes L., Torti F.M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in-vivo andin-vitro. Proc Natl Acad Sci. 87:1990;4275-4279.
24. Jaenke R.S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Canc Res. 36:1976;2958-2966.
25. Katz A.M. The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med. 121:1994;363-371.
26. Kavinsky C.J., Umeda P.K., Levin J.E., Sinha A.M., Nigro J.M., Jakovcic S., Rabinowitz M. Analysis of cloned mRNA sequences encoding subfragment 2 and part of subfragment 1 and alpha- and beta-myosin heavy chains of rabbit heart. J Biol Chem. 259:1984;2775-2781.
27. Kurabayashi M., Raju J., Kedes L. Myogenic toxicity of doxorubicin is associated with the transcriptional activation of the Id gene. Circ. 86:1992;I-F.
28. Kurabayashi M., Dutta S., Kedes L. Activation of the human id-2 gene promoter by the antitumor agent doxorubicin is mediated through elements distinct from the sequences required for phorbol ester- and camp-inducible expression. Circ. 88:1993;I-233.
29. Leonard A., Brown T., Hunter W.N. Anthracycline binding to DNA: high resolution structure of d(TGTACA) complexes with 4′-epiadriamycin. Eur J Biochem. 204:1992;69-74.
30. Lewis W., Galizi M., Puszkin S. Compartmentalization of adriamycin and daunomycin in cultured chick cardiac myocytes. Circ Res. 53:1983;353-362.
31. Lewis W., Gonzales B. Actin isoform synthesis by cultured cardiac myocytes: effects of doxorubicin. Lab Invest. 56:1987;295-301.
32. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 324:1991;808-815.
33. Makino N., Hata T., Sugano M., Dixon I.M.C., Yanaga T. Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type I receptor in rats. J Mol Cell Cardiol. 28:1996;507-517.
34. Mikami A., Imoto K., Tanabe T., Niidome T., Mori Y., Takeshima H., Narumiya S., Numa S. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature. 340:1989;230-233.
35. Oikawa S., Inai M., Inuzuka C., Tawaragi Y., Nakazato H., Matsuo H. Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem Biophys Res Commun. 132:1985;892-899.
36. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4:1990;3076-3086.
37. Otsu K., Willard H.F., Khanna V.K., Zorzato F., Green N.M., MacLennan D.H. Molecular cloning of cDNA encoding the Ca2+release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J Biol Chem. 265:1990;13472-13483.
38. Putney S.D., Herlihy W.C., Schimmel P. A new troponin T and cDNA clones for 13 different muscle proteins, found by shotgun sequencing. Nature. 302:1983;718-721.
39. Rannou F., Dambian G., Marty I., Carre F., Trouve P., Lompre A.M., Charlemagne D. Expression of the cardiac ryanodine receptor in the compensated phase of hypertrophy in rat heart. Cardiovasc Res. 32:1996;258-265.
40. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual, 2nd Ed. New York: Cold Spring Harbor Press. 1989.
41. Schwartz R.G., McKenzie W.B., Alexander J., Sager P., D'Souza A., Manatunga A., Schwartz P.E., Berger H., Setaro J., Surkin L., Wackers FJTh, Zaret B.L. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Medicine. 82:1987;1109-1118.
42. Schwartz K., Boheler K.R., De La Bastie D., Lompre A., Mercadier J.J. Switches in cardiac gene expression as a result of pressure and volume overload. Am J Physiol. 31:1992;R364-R369.
43. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:1998;900-901.
44. Steinherz L.J., Steinherz P.G., Tan C.T.C., Heller G., Murphy L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 266:1991;1672-1677.
45. Steinherz L.J., Steinherz P.G., Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Ped Oncol. 24:1995;352-361.
46. Thekkumkara T.J., Livingston III W, Kumar R.S., Sen G.C. Use of alternative polyadenylation sites for tissue-specific transcription of 2 angiotensin-converting enzyme mRNAs. Nucleic Acids Res. 20:1992;683-687.
47. VonHoff C.J., Layard C.V., Bacerzak S.P., Hamlin R.L. Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med. 91:1979;710-717.
48. Zahringer J. The regulation of protein synthesis in heart muscle under normal conditions and in the adriamycin-cardiomyopathy. Klin Wochenschr. 59:1981;1273-1278.